A B S T R AC T
Background. Little is known about the progression of kidney disease in HIV-infected patients in developing countries in the era of antiretroviral therapy (ART). Methods. HIV-infected patients were screened for kidney disease. Kidney biopsies were performed before and after initiation of ART to assess the clinical and histological response to treatment. Data were collected from all participants in accordance with the study protocol. The mean followup was 2.4 patient years on ART.
Results. There was a rapid immunological and renal response to ART. The renal response was reflected by a significant rise in the estimated glomerular filtration rate (eGFR) and rapid regression of proteinuria. The histological patterns were highly variable, ranging from non-specific lesions such as mesangial hyperplasia and interstitial nephritis to HIVimmune complex disease (HIV-ICD) with or without features of HIV-associated nephropathy (HIVAN). In the follow-up biopsies, the histological response to treatment was variable with a combination of no change, progression or regression of lesions.
Conclusions. This study demonstrated a spectrum of renal histological lesions in HIV-associated kidney disease. Initiation of ART produced a rapid and sustained clinical renal response in all participants, irrespective of the histology. Follow-up biopsies showed an inconsistent histological response of lesions to treatment. In lesions that regressed, there appeared to be a discrete lag in histological response when compared with the rapid clinical response.
I N T R O D U C T I O N
HIV-associated nephropathy (HIVAN) was described, clinically and histologically, as early as 1984 [1] . A spectrum of HIV-associated kidney lesions other than HIVAN have since been described by various authors and were recently reviewed by Wyatt et al. [2] . Patterns of histological lesions have been published from South Africa. Han et al., from Durban, showed that HIVAN occurred in 83% of ambulatory patients with proteinuria and relatively preserved renal function [3] . Gerntholtz et al. [4] reported HIVAN in 27% and HIV-immune complex disease (HIV-ICD) in 21% of hospitalized patients with advanced kidney dysfunction in Soweto, Johannesburg. Okpechi et al. [5] , in Cape Town, showed that HIVAN was the predominant lesion (55%) and initiation of antiretroviral therapy (ART) in those with HIVAN and HIV-ICD significantly enhanced survival. There are no prospective studies, to the authors' knowledge, that have investigated the histological response of biopsy-proven HIVAN and non-HIVAN lesions to ART. This prospective cohort study was undertaken to determine the histological spectrum of HIV-associated renal lesions and to monitor the response to ART with clinical data and follow-up biopsies. ART: stavudine; lamivudine, efavirenz. l ART: stavudine; lamivudine; efavirenz switched to nevirapine. m ART: stavudine, lamivudine, efavirenz; patient developed macrocytic anemia and renal tubular acidosis which responded to replacing stavudine with lopinavir/ritonavir; when the patient fell pregnant the efavirenz was stopped. n ART: lamivudine, efavirenz, lopinavir/ritonavir.
Patients were selected from a cross-sectional urine screening study conducted from February to December 2005 [6] . ARTnaïve HIV-infected adult South Africans attending the outpatient HIV clinic of the Charlotte Maxeke Johannesburg Academic Hospital, South Africa, were screened for persistent microalbuminuria/proteinuria. Urine dipstick testing was done using Combur 9® test strips (Roche Diagnostics). If the test strip was positive for protein, the specimen was sent for laboratory quantification as a spot protein: creatinine ratio (g/ mmol) (Cobas ® , Roche Diagnostics). If the test strip was negative for protein, urine was screened for microalbuminuria (Micral-Test ® Roche Diagnostics). If the test strip for microalbuminuria was positive, it was sent for laboratory quantification as a spot microalbumin: creatinine ratio (mg/mmol).
The definition of microalbuminuria used was as per the local laboratory reference range (see footnote, Table 1 ), measured on two separate occasions, at least 2 weeks apart. Potential causes of albuminuria were considered exclusion criteria: acute illness, significant co-morbid disease (in particular, advanced AIDS, malignancy, tuberculosis), suspected urinary tract infection and sexually transmitted infection, fever, uncontrolled hypertension, uncontrolled diabetes mellitus and intravenous drug use. A serum creatinine of >250 µmol/L was used as a guide to screen those with more advanced kidney disease. CD4 counts and HIV viral loads were measured. In the assessment of the estimated glomerular filtration rate (eGFR), two formulae, the Cockroft Gault (CG) and the Modification of Diet in Renal Disease (MDRD) were used [7, 8] . Patients who underwent a renal biopsy provided written informed consent for the procedure. Renal specimens were submitted for light 
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microscopy, immunofluorescence and electron microscopy where possible. In those who underwent biopsy, serological testing was performed for syphilis, rheumatoid factor, antinuclear antibodies, hepatitis B surface antigen (Hep BsAg), hepatitis C antibodies (Hep C ab). The initiation of ART was based on the stage of HIV infection and not on the presence or absence of HIV-associated kidney disease. ART was commenced after the renal biopsy and the regimens prescribed included lamivudine, stavudine, efavirenz and nevirapine replaced efavirenz in women of childbearing age [9] . Stavudine and lamivudine were dose adjusted for renal function. In March 2007, the WHO recommended dose reductions of stavudine according to weight and appropriate dose adjustments were made [10] . In patients with nephrotic range proteinuria, treatment with an angiotensin-converting enzyme inhibitor (ACE-I), enalapril maleate, was commenced. The dose was titrated against blood pressure, tolerance and clinical response. In those with subnephrotic proteinuria which persisted 3 months after initiation of ART, enalapril maleate was initiated. The immunological response to ART was assessed with HIV viral load, CD4 count. After a minimum of 6 months of ART, a repeat renal biopsy was performed, where possible. Patients provided written informed consent for the second biopsy. Ethics approval was obtained from the Human Research Ethics Committee of the University of Witwatersrand (M040929). Data were analysed using Statsoft ® , Statistica 8 (licensed to University of the Witwatersrand October 2008). Descriptive analyses were carried out with continuous variables being summarized using means, standard deviations and ranges. In cases where data were not normally distributed, non-parametric analyses were performed, in particular, the use of the Wilcoxon matched pairs test for analyses of the effect of treatment on the intervention group. The histology specimens were independently reviewed by two experienced pathologists. 
O R I G I N A L A R T I C L E R E S U LT S
Five hundred and eighty-five ART naïve, HIV-infected adults were screened for proteinuria and data were available for 578 of 585 patients. There were 217 males (37.5%) and 361 females (62.5%), with a mean age of 37 years (range 16-70) and a mean nadir CD4 count of 130 cells/mm 3 (range 1-828). Four hundred and eighty-two participants (83.4%) had CD4 counts <200 cells/mm 3 . The ethnic distribution was 560 black (96.9%), 10 mixed descent (1.7%), 6 white (1%) and 2 not stipulated (0.3%). There was a higher than anticipated prevalence of urinary abnormalities and comorbidity on initial screening, resulting in high exclusion rates across all groups of proteinuria according to the study criteria (subjects and methods section). The prevalent comorbid illnesses, exclusion criteria and outcomes that were available have been summarized in Table 2 . Of those with persistent microalbuminuria/proteinuria, 8 of 11 with microalbuminuria, 4 of 7 with overt proteinuria and 8 of 14 with nephrotic proteinuria gave consent for renal biopsy (Tables 1 and 2) . One patient developed a subcapsular bleed, confirmed with renal angiography, which did not require further intervention. No other biopsy complications occurred. Table 1 depicts clinical and laboratory data for those with persistent microalbuminuria/proteinuria who underwent renal biopsy. Of 20 initial biopsies done, 12 were repeated. In the eight not repeated, six patients were lost to follow-up and two died, both of whom had nephrotic syndrome and declined ART. All other participants were on ART. The mean follow-up time on ART was 2.45 years.
The effect of treatment on immune and renal parameters
The effect of treatment on both immune and renal parameters was analysed using the Wilcoxon matched pairs test. The immune response was assessed by monitoring the preand post-treatment CD4 count and log HIV viral load, where available (Table 1) . Patients 4 and 12 were excluded from the analysis as both reported interrupting treatment. In the remaining patients, the median CD4 count (n = 12) pre-treatment was 107.5 cells/mm 3 [interquartile range (IQR) 88-214.5] and post-treatment was 417 cells/mm 3 (IQR 313.5-629.5; P < 0.005) over an average period of 2.45 years (range 0-4 years) and the median log HIV viral load (n = 10) over the same time period was 5.49 RNA copies/mL (IQR log 2.34-5.81) pre-treatment and <log 1.6 RNA copies/mL post-treatment; (P < 0.01). Renal response was assessed by monitoring pre-and post-treatment microalbuminuria/proteinuria and eGFR. The median microalbuminuria/proteinuria (n = 16) pre-treatment was 0.088 g/mmol (IQR 0.0075-0.58) and post treatment was 0.0032 g/mmol (IQR 0.0012-0.017; P < 0.005). The reduction or regression of microalbuminuria/proteinuria occurred in all patients with available data, that is, a 100% response rate to treatment. The antiproteinuric response was rapid, occurring largely within the first 6 months, and sustained for the duration of treatment. The effect of treatment on the eGFR (n = 12) was analysed using two formulae: CG and MDRD. With CG, the median pre-treatment eGFR was 86. 
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with microalbuminuria showed no change in eGFR and the remainder showed an improved eGFR on treatment. Table 1 summarizes complications of ART and co-morbid conditions that developed while on treatment. It was not within the scope of the study to perform extended virological serology on those who tested positive for Hep BsAg. With regard to hypertension, Patient 10 was on treatment for hypertension which was controlled at the time of screening. He was maintained on an ACE-I, a calcium channel blocker and hydrochlorothiazide for the duration of follow-up. Four other patients (2, 3, 6, 18) developed hypertension at variable times after initiation of ART (3, 11, 20, 9 months, respectively) and at this time, an ACE-I was initiated. Two patients were prescribed oral prednisone after the initial biopsy: one was for treatment of suspected pneumocystis Jiroveci pneumonia and the other for crescentic glomerulonephritis. Both were lost to follow-up.
Comorbid conditions and complications on treatment
Renal histology prior to antiretroviral therapy A spectrum of glomerular lesions was noted in the 20 initial biopsy specimens (see Table 3 for details). In summary, the most common lesions found were HIV-ICD (4/20) (Figures 2a and 3a) ; mesangial hyperplasia with chronic interstitial nephritis (MH + CIN) (4 of 20) (Figure 1 ) and global glomerulosclerosis (GS) with CIN (2 of 20). When grouped according to the severity of proteinuria, no single glomerular lesion predominated in any one of the three groups.
The HIV-associated immune-complex disease (HIV-ICD) in this series was characterized by variable mesangial alterations, accompanied by mesangial/paramesangial-based immune deposits. Immune deposits comprised IgG, IgM and complement C3 in relation to the glomerular basement membranes and were subepithelial in location. In some cases (Patients 3, 7), these deposits were associated with a basement membrane reaction to the deposits, in the form of localized spike formations, resulting in a 'ball-in-cup' reaction pattern, with the 'ball' representing the immune-deposit and the 'cup' representing the localized basement membrane reaction around the immune deposit (Figure 2a and c) . The glomerular basement membrane holes (GBMH) described in this series are thought to be residual glomerular basement membrane defects from immune complexes that have been cleared (Figure 2b) . On ultrastructural examination, epithelial cell foot process effacement was noted in all 20 patients. The overall cross-sectional area of the epithelial cell foot process effacement was not quantified in the initial and follow-up biopsy specimens.
Renal histology following antiretroviral therapy
The initial and repeat renal histology results are summarized in Table 3 . Follow-up biopsies were obtained from 12 patients. They were performed after variable times on ART (range 7-39 months). When comparing initial with repeat histology, there were no changes seen in four patients; progression of lesions in three patients (two of whom reported interrupting ART) and regression/improvement of lesions in five patients. Two patients (3, 17) deserve special consideration. The follow-up biopsy in Patient 3 (HIV-ICD) was performed at 7 months and partial resolution of immunecomplex deposits was noted. Based upon this finding, it was decided to extend the time on ART to ∼1 year before repeating biopsies to allow more time for clearance of immune complexes. This patient agreed to a repeat biopsy after completing 25 months of ART. Comparison of the three biopsies shows time-dependent, but incomplete resolution of immune-complex deposits (Figure 2a and b ; Table 4 ) and persistence of the chronic active interstitial nephritis (Figure 2b ). Patient 17 showed complete or near complete resolution of the immune-complex mediated glomerular disease process; microcystically dilated tubules and mesangial hyperplasia but a persistent chronic active interstitial nephritis (Figure 3a-c) .
D I S C U S S I O N
This is the only study, to the author's knowledge, that has prospectively documented both the clinical and histological 
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responses of biopsy-proven HIV-associated renal lesions to ART. Of note, this study has observed changes in the early stages of biopsy-proven HIV-associated kidney disease, as demonstrated by the initial eGFR of 104.5 mL/min (MDRD equation). It is also unique in that it has prospectively evaluated the effect of treatment on predominantly non-HIVAN lesions and HIVAN-plus lesions (i.e. having some features of the classic 'HIVAN' in combination with others such as immune-complex deposition) and demonstrated the pattern of regression of microalbuminuria/proteinuria after initiation of ART. In addition, we demonstrated a relatively rapid regression of proteinuria and improvement in eGFR, after starting ART, which did not correlate with a slow and attenuated histological response to treatment on follow-up renal biopsies.
In the clinical response to ART, we have shown marked improvement in immune parameters with excellent viral suppression and rises in median CD4 counts. The renal response to treatment was also impressive. The mean pre-treatment eGFR would be accepted as close to normal (>85 mL/min/ 1.73 m 2 mL/min) irrespective of the formulae used, and there was a statistically significant rise in eGFR on treatment. This has been demonstrated in other epidemiological studies [11, 12] . There was partial regression or complete remission of proteinuria in response to treatment, with or without ACE inhibition. This was demonstrated across all ranges of proteinuria; the response was rapid in all patients (within the first 3-6 months) and sustained for the duration of treatment. In those for whom ACE-I was initiated because of the onset of hypertension, the antiproteinuric effect occurred prior to initiation of ACE-I. The improvement in renal function in response to ART, particularly of non-HIVAN lesions seen in this study and that from Cape Town, challenges the findings of Szczech et al., who concluded that the use of ART was not associated with a beneficial effect on renal function in non-HIVAN lesions [5, 13] . Furthermore, patients in our study did not show deterioration in renal function, unlike the reports of Bige et al., which showed progression with advanced CKD or a high index of chronic damage initially [14] . This may be due to our patients initiating treatment at earlier stage of kidney disease than their study. These findings support further investigation into non-invasive ways of diagnosing HIV-associated kidney disease (microalbuminuric) which would support early initiation of ART, particularly in patients with high CD4 counts who would otherwise have no indication to commence treatment.
The diversity of the histological findings on the initial 20 renal biopsies deserves mention for a few reasons. First, there was no clustering of specific lesions according to the degree of proteinuria, for example, HIV-associated ICD occurred with microalbuminuria (Patients 3, 7) and nephrotic proteinuria (Patients 17, 18). This highlights that established lesions can occur in the presence of persistent microalbuminuria in HIV infection, as previously reported by Han et al. [3] . The contradiction of this study, however, lies in the paucity of HIVAN lesions, which predominated in Han's study. Second, histological changes were demonstrated in the absence of co-morbid clinical pathology that could not be classified as 'HIV-related' according to the currently accepted histological criteria. Some of these lesions (mesangial hyperplasia in Patients 6, 17, 18) were both non-specific and unclassified yet they showed resolution in response to ART. This implies that they may be related to the presence of HIV within the renal compartment and could represent a snapshot of a process in evolution. The demonstration of regression of immunecomplex deposits (Tables 3 and 4 ) also provides supporting evidence for a direct role of HIV infection in immunecomplex-mediated kidney disease, as suggested by Kimmel et al. [15] . There are also some lesions, CIN in particular, that appear to be resistant to ART. Our findings may suggest a differential sensitivity of various compartments within the kidney to HIV in the early stages of kidney disease. Our findings also support the need for reviewing the histological classification for HIV-associated kidney disease, which appears to be incomplete, according to the findings in this and other studies from South Africa [4, 5] . Third, the discrepancy between a rapid clinical response to ART (regression of proteinuria and rise in eGFR) was in stark contrast to the relative lack of histological resolution (but for a few cases). This was demonstrated (Table 4 ; Figure 2a and 2b) in successive biopsies that demonstrated progressive elimination of immune-complex deposition at 7 and 25 months of ART (Patient 3). When comparing the pre-and post-treatment histology specimens, there was no striking change in the morphological appearances on light microscopic examination of the glomerular lesions in any of the three clinical groups to readily explain the dramatic improvement in proteinuria. It is certainly plausible that the rapid improvement in the proteinuria noted on follow-up is possibly related to the degree and extent of epithelial cell foot process effacement, which we did not quantify, with regard to the extent of glomerular capillary wall surface area involved, in either the initial and/or follow-up biopsy specimens. Study limitations include that patients were recruited at a single site, which partly functions as a referral centre. It should also be noted that the study population was of black African descent and ART naïve and generalization of the findings to US and European populations should be cautioned. In addition, the sample size is limited, consent was not obtainable for biopsy for all patients, and there was significant loss to follow-up. In spite of these limitations, this study does offer an unprecedented look at the histological response to ART in non-HIVAN kidney disease.
CO N C L U S I O N
This study has demonstrated a rapid virological and renal response to ART in HIV-infected South Africans with histologically documented HIV-associated kidney disease, irrespective of the histology. This rapid clinical response, as measured by regression of proteinuria and rise in the eGFR, did not correlate with the variable and delayed histological findings on follow-up biopsies. There was a variable response to treatment of non-specific histological lesions that may be the early component of a process in evolution-this may require a review of the classification system for the histology of HIV-associated kidney disease, particularly in the early stages. Non-HIVAN and HIVAN-plus lesions responded both histologically and clinically to ART and could be considered an indication for treatment. Clinicians should be mindful that persistent microalbuminuria in HIV infection, in the absence of other reversible causes, may represent established HIV-associated renal lesions that could benefit from ART. Further research is needed to investigate non-invasive diagnostic markers to assist with decision making regarding the initiation of treatment, especially in those with high CD4 counts and no other indications for initiation of ART.
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